STAR Medical

current vacancies from:

company in focus

Actelion Pharmaceuticals Ltd

Biopharmaceutical company Actelion Pharmaceuticals Ltd, whilst based in Switzerland, has a far-reaching global presence, featuring subsidiaries within marketing and sales in over 20 countries, covering all major pharmaceutical markets. Their aim is to discover, develop and commercialise innovative treatments that address unmet medical needs.

Actelion prioritise partnership and innovation; they actively encourage project management to the mutual, strategic and financial benefit of selected partners, and leverage the benefits of these partnerships to expand their research and development facilities.

An example of Actelion Partnerships:

-In-licensing	-Partnerships	-Acquisitions
-Nippon Shinyaku	-GlaxoSmithKline	-Axovan
-Bayer Schering Pharma AG	-F. Hoffmann-La Roche	-CoTherix Inc.
-Oxford GlycoScience	-Merck & Co., Inc

The company culture has been carefully cultivated to inspire a working environment that vivifies innovation. Trust, teamwork and open communication are encouraged to ensure an enthusiastic and stimulating environment for creative thinking, which Actelion translate to innovative thinking. They have removed perceived inhibitive creative factors, namely bureaucracy and hierarchy, to empower their employees to innovate.

Actelion also work hard to ensure their employees feel valued. The Actelion bonus scheme was conceived to allow employees to participate in the success of the company they have contributed to; the scheme is based upon the achievement of group, departmental, and individual goals assessed in relation to the growth predictions of the company. The Actelion Equity Plan is also designed to reward employees as the company continues to flourish, as is the Actelion Share Challenge. Employees are also rewarded with a range of competitive benefits developed and implemented locally, with the aim of properly addressing the diverse needs of a global team.

Actelion have also created The Actelion Endothelin Research Awards (AERA); the grant-based program, which began in 2006, targets young investigators with the objective to encourage clinical endothelin research related to heart, lung and vascular disease. This global program also includes the Entelligence program in the US.
Applications are evaluated by the AERA Steering Committee, an independent board of experts who decide on the awarding of the grants, and provide strategic guidance to the AERA program. The latest figures accumulated in October 2008 show that 12 outstanding projects from 7 different countries had received awards.

When it comes to research and development, Actelion adopt a drug hunting approach, focusing their efforts as a team, adopting an inquisitive, pioneering and bold approach.

A selection of Actelion products:

Tracleer - currently licensed for the treatment of pulmonary arterial hypertension. In the EU, Tracleer is also indicated to reduce the number of new digital ulcers in patients with systematic sclerosis, and ongoing digital ulcer disease.

Zavesca - small molecule therapy for the oral treatment of mild to moderate type 1 Gaucher disease. May only be used in the treatment of patients for whom enzyme replacement therapy is unsuitable.

Ventavis - is an inhaled formulation of iloprost, approved for the treatment of pulmonary arterial hypertension.

Actelion Development Pipeline:

-Phase-	-Product/Compound-	-Indication	-Study	-Results -expected-
-IV	-Bosentan	-Combination bosentan&sildenafil -in PAH	-COMPASS – 2	-N/A
-IV	-Iloprost	-Pulmonary arterial hypertension -(improved system delivery)	-N/A	-N/A
-IV	-Miglustat	-Type 1 Gaucher disease patients- -switched from ERT to miglustat	-MAINTENANCE-	-2010
-III	-Almorexant	-Sleep disorders	-RESTORA	-N/A
-III	-Bosentan	-Idiopathic pulmonary fibrosis	-BUILD-3	-H2 2009-
-III	-Clazosentan	-Vasospasm as consequence of -aneurysmal subarchnoid -hemorrhage	-CONSCIOUS-2	-H2 2009
-III	-Macitentan	-Pulmonary arterial hypertension	-SERAPHIN	-N/A
-II	-CRTH2 antagonist	-Allergy	-N/A	-2009
-II	-Miglustat	-Cystic fibrosis	-N/A	-2009
-II	-PGI2 agonist	-Pulmonary arterial hypertension	-N/A	-N/A
-I	-Renin inhibitor	-Cardiovascular	-N/A	-N/A
-I	-S1P1 agonist	-Immunology	-N/A	-2008

This information has been collated from text originally published at www.actelion.com; to read about Actelion, their products and activities please visit www.actelion.com.

Solutions you need. People you trust.

company in focus

Actelion Pharmaceuticals Ltd

An example of Actelion Partnerships:

A selection of Actelion products:

Actelion Development Pipeline:

industry profiles

Pharmaceutical

Healthcare